Cost-effectiveness and budget impact analysis of pembrolizumab as an adjuvant treatment of resected stage III melanoma from an Australian healthcare system perspective

Journal of Cancer Policy · Elsevier

Аннотация

Publication date: September 2026 Source: Journal of Cancer Policy, Volume 49 Author(s): Rashidul Alam Mahumud

Читать у издателя →

Похожие статьи